ArticleJCO oncology practice2026
Impact of a Precision Medicine Navigator on Genomic Test Utilization in Black Patients With Prostate Cancer.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discordant molecular biomarkers in unfavorable intermediate-risk localized prostate cancer.CA: a cancer journal for cliniciansArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
purposeAs oncologic precision medicine develops, there is concern that tumor genomic profiling among Black patients and other underrepresented demographics will lag and amplify health disparities. We evaluate whether a precision medicine navigator (PMN), a clinical navigator specialized in obtaining tumor genomic testing for patients, is associated with increased genomic testing rates and whether this is the case among Black patients and other disadvantaged groups.
methodsWe retrospectively reviewed prostate cancer consults within one health care system from November 2, 2021, to January 2, 2023. We compared the proportion of patients who received genomic testing in the 7 months before the PMN start (pre-PMN) to the 7 months afterward (post-PMN). Binary logistic regression was used to calculate the odds of receiving testing.
resultsThe sample included 693 patients, 311 pre-PMN and 382 post-PMN. Racial distribution and clinical stage were well-balanced between the pre- and post-PMN groups. From pre- to post-PMN, the proportion of patients receiving testing increased from 18% to 70% (
conclusionFor patients with prostate cancer, the presence of a PMN is associated with increased rates of genomic testing overall, including among Black patients and other groups that experience health inequities. Utilization post-PMN was significantly lower in Black patients compared with non-Black patients. More research is needed into why Black patients show lower rates of genomic testing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.